Lotus Pharmaceutical Co Ltd (1795)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Lotus Pharmaceutical Co Ltd (1795)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH202295D
  • |
  • Pages: 20
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Lotus Pharmaceutical Co Ltd (Lotus), a subsidiary of Alvogen Inc is a pharmaceutical company that develops and sells pharmaceutical products. The company provides products that are used in the treatment of cardiology, rheumatology, cancer, woman healthcare, oncology, dyslipidemia, hypertension, auto immune, nephrology, gastrointestinal, and central nervous system. It offers services such as research and development, contract manufacturing, and contract research. Lotus also provides biosimilars, an alternative to existing biological medicinal products. The company exports its products to Japan and Korea. It operates in India, China, Korea, Malaysia, Thailand, Myanmar, Vietnam, Hong Kong and Philippines. Lotus is headquartered in Taipei, Taiwan.

Lotus Pharmaceutical Co Ltd (1795)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Licensing Agreements 10

Luye Pharma Enters into Licensing Agreement with Lotus Pharma 10

TMRC Enters Into Licensing Agreement With EPS And Lotus Pharma For TM-411 11

Asset Transactions 12

Lotus Pharma Plans to Sell Product Rights 12

Acquisition 13

Alvogen To Acquire 67% Stake In Lotus Pharma For USD205 Million 13

Lotus Pharmaceutical Co Ltd-Key Competitors 14

Lotus Pharmaceutical Co Ltd-Key Employees 15

Lotus Pharmaceutical Co Ltd-Locations And Subsidiaries 16

Head Office 16

Other Locations & Subsidiaries 16

Recent Developments 17

Corporate Communications 17

Dec 19, 2016: Lotus Chairman Charles Lin Retires; Director Andrew Lin Steps Up as New Chairman 17

Legal and Regulatory 18

Feb 17, 2016: Lotus' Manufacturing Facilities In Nantou Successfully Passed US FDA's Inspection 18

Product News 19

06/13/2016: Lotus ANDA Of Levetiracetam ER Tablets Has Been Officially Approved By US FDA 19

Appendix 20

Methodology 20

About GlobalData 20

Contact Us 20

Disclaimer 20

List of Figures

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Lotus Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8

Lotus Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Luye Pharma Enters into Licensing Agreement with Lotus Pharma 10

TMRC Enters Into Licensing Agreement With EPS And Lotus Pharma For TM-411 11

Lotus Pharma Plans to Sell Product Rights 12

Alvogen To Acquire 67% Stake In Lotus Pharma For USD205 Million 13

Lotus Pharmaceutical Co Ltd, Key Competitors 14

Lotus Pharmaceutical Co Ltd, Key Employees 15

Lotus Pharmaceutical Co Ltd, Other Locations 16

Lotus Pharmaceutical Co Ltd, Subsidiaries 16

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Lotus Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16005
Site License
USD 500 INR 32010
Corporate User License
USD 750 INR 48015

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com